Comprehensive Genetic Analysis of Non-syndromic Autism Spectrum Disorder in Clinical Settings.

Ohashi et al. (2021) ran full genetic work-ups on children who had autism but no known syndrome. They used chromosome micro-arrays and whole-exome sequencing to hunt for clear-cut, single-gene causes. The goal was to see how often these expensive tests give families a firm answer.

Only one in ten families received a conclusive genetic finding. The other ninety percent walked away with 'variants of unknown significance' that doctors cannot yet interpret. In short, current high-tech panels rarely explain non-syndromic autism.

Beaumont et al. (2008) found strong links between the MET pathway and autism risk. Their positive results clash with Kei's low yield, but the difference is scope: B et al. hunted one pathway in a research sample, while Kei scanned the entire genome in everyday patients. Torske et al. (2020) also showed that common genetic risk scores predict day-to-day executive problems, proving genes matter even when single-gene tests come back blank. İnci et al. (2021) add another layer: metabolic screening caught six rare inborn errors among 247 ASD referrals. Together these papers say: keep looking beyond the basic gene panel—both polygenic risk and metabolic routes can still yield actionable data.

When parents ask 'Why did this happen?' you can now give them realistic numbers: comprehensive DNA testing gives a clear cause only ten percent of the time. Use this fact to set expectations before ordering tests. Pair the DNA work with metabolic labs or polygenic-risk counseling when clinically indicated, and always schedule a post-test session to explain the sea of 'unknown' variants. This balanced approach saves money, reduces family stress, and keeps the clinical focus on skill-building interventions that help the child today.